ArticleAnatolian journal of cardiology2025
Evaluation of Spandan Smartphone-Based Electrocardiogram for Arrhythmia Detection: A Cross-Sectional Study in a Large Patient Cohort.
Article in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the diagnostic accuracy of the Spandan Lead II smartphone-based electrocardiogram (ECG) device regarding cardiac arrhythmia, compared with that of the only lead II ECG strip from the gold-standard ECG machine (BPL ECG machine) and the diagnosis by a cardiologist.
methodsThe study, conducted from August 2, 2022, to June 2, 2023, in the local hospital, included 2799 participants aged 20 years and above. This was a single-blinded, cross-sectional study comparing the Spandan ECG device against the Gold Standard ECG and was diagnosed by a cardiologist. Participants referred for ECG testing by a cardiologist were included, and those with a pacemaker and/or ECG artifacts were excluded. To avoid any bias, the diagnosis was blinded to the cardiologist. Sensitivity, specificity, predictive values, F-score, and Matthew's correlation coefficient of the Spandan device were the parameters on which accuracy was studied.
resultsAmong 2799 participants (843 females, 1,956 males), the Spandan ECG system demonstrated high accuracy compared to the gold standard ECG machine, with sensitivity (95.5%), specificity (96.3%), positive predictive value (93.2%), negative predictive value (97.6%), F-Score (0.94), and a P = .913, for P > .001. It identified all arrhythmias without discrepancies and closely aligned with the gold standard ECG, which had slightly lower performance metrics. The study concluded that the Spandan Lead II ECG system is clinically applicable, especially in resource-limited settings.
conclusionThe Spandan lead II smartphone-based ECG device offers high accuracy in diagnosing cardiac arrhythmias, comparable to standard ECG machines. Its portability, affordability, and ease of use make it a valuable tool for timely diagnosis in almost all clinical and non-clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.